A Randomized Trial of Bictegravir or Dolutegravir with Emtricitabine and Tenofovir Alafenamide (F/TAF) Followed by Open Label Switch to Bictegravir/F/TAF Fixed Dose Combination

BACKGROUND: Integrase strand transfer inhibitors (INSTIs) are widely recommended for initial HIV-1 treatment. Bictegravir (BIC, B) is a novel, once-daily INSTI with potent antiviral activity being developed in coformulation with emtricitabine and tenofovir alafenamide (F/TAF). METHODS: In this Phase...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Open Forum Infect Dis
Main Authors: Sax, Paul E, Dejesus, Edwin, Crofoot, Gordon, Ward, Douglas, Benson, Paul, Wei, Lilian, White, Kirsten, Collins, Sean, Martin, Hal, Cheng, Andrew, Quirk, Erin
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2017
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5630742/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofx163.1076
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados